CA AB2203

Caps copayments for insulin prescriptions at $50 per 30-day supply and $100 total per month for health care service plans and disability insurance policies issued, amended, delivered, or renewed on or after January 1, 2021, regardless of insulin amount or type.

Prohibits deductibles, coinsurance, or other cost-sharing requirements on insulin prescriptions except for the capped copayment, applying to both health care service plans and specified disability insurance policies.

Authorizes the Attorney General to investigate prescription insulin drug pricing across the supply chain and issue a public report by November 1, 2022 with findings and policy recommendations.

Exempts trade secrets and proprietary business information submitted to the Attorney General from California Public Records Act disclosure requirements.

Sunsets the copayment limitations and Attorney General investigation provisions on January 1, 2024.